Memory rehabilitation for people with multiple sclerosis

Nair, Roshan das; Martin, Kristy-Jane; Lincoln, Nadina B.

doi:10.1002/14651858.cd008754.pub3

Cited by 91 publications

(48 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although meta-analyses report no to little evidence with respect to the effectiveness of cognitive rehabilitation to improve memory function (Thomas, Thomas, Hillier, Galvin, & Baker, 2006;dasNair et al, 2012;Rosti-Otajärvi & Hämäläinen, 2014;dasNair et al, 2016), participant reports indicate perceived improvements in functioning.…”

Section: Positive Impact On Quality Of Lifementioning

confidence: 99%

“…Although some randomised controlled trials (RCTs) have demonstrated its effectiveness (Carr, dasNair, Schwartz, & Lincoln, 2014;Hildebrandt et al, 2007), findings from some systematic reviews on memory rehabilitation for people with MS (Brissart et al, 2011;dasNair, Ferguson, Stark, & Lincoln, 2012) do not. The dasNair, Martin, and Lincoln (2016) Cochrane review found some evidence to support the effectiveness of memory rehabilitation for people with MS, but this was limited to objective measures of memory and quality of life. Qualitative studies, however, have suggested that cognitive rehabilitation may be helpful for people with MS with attention problems (Stuifbergen, Becker, Morgan, Morrison, & Perez, 2011) and memory problems (dasNair & Lincoln, 2013).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of cognitive rehabilitation for people with multiple sclerosis: a meta-synthesis of patient perspectives

Klein

Drummond

Mhizha-Murira

et al. 2017

Neuropsychological Rehabilitation

View full text Add to dashboard Cite

While previous randomised controlled trials and meta-analyses offer only limited evidence for the effectiveness of cognitive rehabilitation, qualitative studies examining patient perspectives report more positive outcomes. This meta-synthesis of qualitative studies examined patient perspectives of cognitive rehabilitation for memory, attention, and executive function problems in people with multiple sclerosis. Using set eligibility criteria, we screened electronic databases, reference lists, and academic networks for

show abstract

Section: Positive Impact On Quality Of Lifementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effectiveness of cognitive rehabilitation for people with multiple sclerosis: a meta-synthesis of patient perspectives

Klein

Drummond

Mhizha-Murira

et al. 2017

Neuropsychological Rehabilitation

View full text Add to dashboard Cite

show abstract

“…Studies were hampered by mixed disease phenotypes, short durations, and differing outcome measures. A third Cochrane review 13 concluded that there was limited evidence for memory rehabilition techniques and that more rigorous trial evidence was needed. The effects of exercise on cognition in multiple sclerosis has also been examined, with a pilot study in 42 patients showing some effect of high-intensity aerobic training on learning, memory, and attention 14 …”

Section: Introductionmentioning

confidence: 99%

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial

Chan

Binks

Nicholas

et al. 2017

The Lancet Neurology

105

View full text Add to dashboard Cite

SummaryBackgroundIn the 24-month MS-STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the annualised rate of whole brain atrophy in patients with secondary progressive multiple sclerosis (SPMS). We now describe the results of the MS-STAT cognitive substudy, in which we investigated the treatment effect on cognitive, neuropsychiatric, and health-related quality-of-life (HRQoL) outcome measures.MethodsWe did a secondary analysis of MS-STAT, a 24-month, double-blind, controlled trial of patients with SPMS done at three neuroscience centres in the UK between Jan 28, 2008, and Nov 4, 2011. Patients were randomly assigned (1:1) to either 80 mg simvastatin (n=70) or placebo (n=70). The cognitive assessments done were the National Adult Reading Test, Wechsler Abbreviated Scale of Intelligence, Graded Naming Test, Birt Memory and Information Processing Battery (BMIPB), Visual Object and Space Perception battery (cube analysis), Frontal Assessment Battery (FAB), and Paced Auditory Serial Addition Test. Neuropsychiatric status was assessed using the Hamilton Depression Rating Scale and the Neuropsychiatric Inventory Questionnaire. HRQoL was assessed using the self-reported 36-Item Short Form Survey (SF-36) version 2. Assessments were done at study entry, 12 months, and 24 months. Patients, treating physicians, and outcome assessors were masked to treatment allocation. Analyses were by intention to treat. MS-STAT is registered with ClinicalTrials.gov, number NCT00647348.FindingsBaseline assessment revealed impairments in 60 (45%) of 133 patients on the test of frontal lobe function (FAB), and in between 13 (10%) and 43 (33%) of 130 patients in tests of non-verbal and verbal memory (BMIPB). Over the entire trial, we noted significant worsening on tests of verbal memory (T score decline of 5·7 points, 95% CI 3·6–7·8; p<0·0001) and non-verbal memory (decline of 6·8 points, 4·8–8·7; p<0·0001). At 24 months, the FAB score was 1·2 points higher in the simvastatin-treated group than in the placebo group (95% CI 0·2–2·3). The simvastatin group also had a 2·5 points better mean physical component score of the SF-36 (95% CI 0·3–4·8; p=0·028). A treatment effect was not noted for any other outcomes.InterpretationTo our knowledge, this SPMS cohort is the largest studied to date with comprehensive longitudinal cognitive, neuropsychiatric, and HRQoL assessments. We found evidence of a positive effect of simvastatin on frontal lobe function and a physical quality-of-life measure. Although we found no effect of simvastatin on the other outcome measures, these potential effects warrant confirmation and underline the importance of fully assessing cognition and quality of life in progressive multiple sclerosis treatment trials.FundingThe Moulton Foundation, the Berkeley Foundation, the Multiple Sclerosis Trials Collaboration, the Rosetrees Trust, a personal contribution from A W Pidgley CBE, and the National Institute for Health Research University College London Hospitals Biomedical Research Centre and University ...

show abstract

“…While the previously mentioned positive results regarding the efficacy of cognitive rehabilitation interventions in MS individuals cannot be overstated, it is important to note that a recently published Cochrane Review that included 15 studies and 989 MS participants regarding the efficacy of memory retraining techniques with or without the assistance of computer software, concluded that there is only limited evidence on the effectiveness of memory rehabilitation in this population. The authors further suggest that more RCTs of high methodological quality be conducted with the utilization of ecologically valid outcome assessments [63].…”

Section: Cognitive Neurorehabilitation In Multiple Sclerosismentioning

confidence: 99%

Neuropsychological Functions and Cognitive Neurorehabilitation in Multiple Sclerosis

Messinis¹,

Nasios²,

Papathanasopouos³

2019

Multiple Sclerosis [Working Title]

View full text Add to dashboard Cite

Although cognitive difficulties are not frequently reported by patients among the initial symptoms of Multiple Sclerosis (MS), there is sufficient evidence that cognitive impairment is present from the early stage of the disease. Today it is commonly accepted that roughly one-half of individuals with MS will experience cognitive dysfunction over the course of the disease. Though MS was originally considered a disease of white matter, more recent investigations with advanced immunohistochemistry techniques have revealed that demyelination of gray matter is a common neuropathological feature in MS contributing significantly to cognitive impairment. However, despite now been recognized as a core symptom of MS, evidence up till now is only modest regarding the efficacy of pharmacological agents on cognitive dysfunction and non-pharmacological interventions such as cognitive rehabilitation also provide incomplete evidence on whether they might improve or stabilize cognitive impairment and especially over long follow up periods. Despite this general consensus, there are studies that have reported the efficacy of cognitive neurorehabilitation in reducing MS associated cognitive deficits. In this chapter we provide a selective review of the most relevant features related to this topic.

show abstract

Memory rehabilitation for people with multiple sclerosis

Abstract: Memory rehabilitation for people with multiple sclerosis.

Cited by 91 publications

References 82 publications

Effectiveness of cognitive rehabilitation for people with multiple sclerosis: a meta-synthesis of patient perspectives

Effectiveness of cognitive rehabilitation for people with multiple sclerosis: a meta-synthesis of patient perspectives

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial

Neuropsychological Functions and Cognitive Neurorehabilitation in Multiple Sclerosis

Contact Info

Product

Resources

About